123 related articles for article (PubMed ID: 7520380)
1. Urinary endothelin-1-like immunoreactivity in young male patients with testicular cancer treated by cis-platinum: comparison with other urinary parameters.
Takeda M; Komeyama T; Tsutsui T; Mizusawa T; Go H; Hatano A; Tanikawa T
Clin Sci (Lond); 1994 Jun; 86(6):703-7. PubMed ID: 7520380
[TBL] [Abstract][Full Text] [Related]
2. Changes in urinary excretion of endothelin-1-like immunoreactivity in patients with testicular cancer receiving high-dose cisplatin therapy.
Takeda M; Komeyama T; Tsutsui T; Mizusawa T; Go H; Hatano A; Tanikawa T
Am J Kidney Dis; 1994 Jul; 24(1):12-6. PubMed ID: 8023817
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin-induced urinary endothelin excretion.
Ohta K; Hirata Y; Shichiri M; Ichioka M; Kubota T; Marumo F
JAMA; 1991 Mar; 265(11):1391-2. PubMed ID: 1999877
[No Abstract] [Full Text] [Related]
4. Measurement of urinary endothelin-1-like immunoreactivity and comparison with other urinary parameters in patients with primary vesicoureteral reflux. A preliminary report.
Takeda M; Komeyama T; Katayama Y; Tsutsui T; Mizusawa T; Takahashi H; Hatano A; Obara K; Sato S
Eur Urol; 1994; 25(4):326-9. PubMed ID: 8056026
[TBL] [Abstract][Full Text] [Related]
5. Value of urinary endothelin-1 in patients with primary vesicoureteral reflux.
Komeyama T; Takeda M; Katayama Y; Tsutsui T; Mizusawa T; Takahashi H; Hatano A; Obara K; Sato S
Nephron; 1993; 65(4):537-40. PubMed ID: 8302406
[TBL] [Abstract][Full Text] [Related]
6. Urinary excretion of endothelin-1 in normal subjects and patients with renal disease.
Ohta K; Hirata Y; Shichiri M; Kanno K; Emori T; Tomita K; Marumo F
Kidney Int; 1991 Feb; 39(2):307-11. PubMed ID: 2002644
[TBL] [Abstract][Full Text] [Related]
7. Changes in urinary excretion of endothelin-1-like immunoreactivity before and after unilateral nephrectomy in humans. Comparison with other urinary parameters and unilateral adrenalectomy.
Takeda M; Komeyama T; Tsutsui T; Mizusawa T; Katayama Y; Go H; Tamaki M; Hatano A
Nephron; 1994; 67(2):180-4. PubMed ID: 8072606
[TBL] [Abstract][Full Text] [Related]
8. Assessment of renal function during high-dose cis-platinum therapy in patients with ovarian carcinoma.
Buamah PK; Howell A; Whitby H; Harpur ES; Gescher A
Cancer Chemother Pharmacol; 1982; 8(3):281-4. PubMed ID: 6127169
[TBL] [Abstract][Full Text] [Related]
9. Urinary excretion of alanine-aminopeptidase and N-acetyl-beta-D-glucosaminidase during sequential combination chemotherapy.
Diener U; Knoll E; Ratge D; Langer B; Wisser H
J Clin Chem Clin Biochem; 1982 Sep; 20(9):615-9. PubMed ID: 6183389
[TBL] [Abstract][Full Text] [Related]
10. Comparison of methods of evaluating nephrotoxicity of cis-platinum.
Jones BR; Bhalla RB; Mladek J; Kaleya RN; Gralla RJ; Alcock NW; Schwartz MK; Young CW; Reidenberg MM
Clin Pharmacol Ther; 1980 Apr; 27(4):557-62. PubMed ID: 6987030
[TBL] [Abstract][Full Text] [Related]
11. Infusion of radiocontrast agents induces exaggerated release of urinary endothelin in patients with impaired renal function.
Fujisaki K; Kubo M; Masuda K; Tokumoto M; Hirakawa M; Ikeda H; Matsui R; Matsuo D; Fukuda K; Kanai H; Hirakata H; Iida M
Clin Exp Nephrol; 2003 Dec; 7(4):279-83. PubMed ID: 14712357
[TBL] [Abstract][Full Text] [Related]
12. Vinblastine, actinomycin D, bleomycin, cyclophosphamide and cis-platinum for advanced germ cell testis tumors: Brazilian experience.
Srougi M; Simon SD; de Góes GM
J Urol; 1985 Jul; 134(1):65-9. PubMed ID: 2409300
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of methods for evaluating the nephrotoxicity of cisplatin].
Suzumori K; Yasui Y; Suzumori K; Yagami Y; Seki T
Gan To Kagaku Ryoho; 1988 Aug; 15(8):2251-6. PubMed ID: 3044273
[TBL] [Abstract][Full Text] [Related]
14. Urinary 28-kD calbindin-D as a new marker for damage to distal renal tubules caused by cisplatin-based chemotherapy.
Takashi M; Zhu Y; Miyake K; Kato K
Urol Int; 1996; 56(3):174-9. PubMed ID: 8860739
[TBL] [Abstract][Full Text] [Related]
15. Urinary endothelin-1-like immunoreactivity excretion in the newborn period.
Kojima T; Isozaki-Fukuda Y; Sasai M; Hirata Y; Matsuzaki S; Kobayashi Y
Am J Perinatol; 1993 May; 10(3):220-3. PubMed ID: 8517899
[TBL] [Abstract][Full Text] [Related]
16. Urinary excretion of beta 2-microglobulin and N-acetyl-beta-D-glucosaminidase in advanced neuroblastoma patients receiving cis-diamminedichloroplatinum(II).
Ikeda H; Nagashima K; Okumura H; Takahashi A; Matsuyama S; Nagamachi Y
Eur J Surg Oncol; 1988 Feb; 14(1):17-20. PubMed ID: 3278937
[TBL] [Abstract][Full Text] [Related]
17. [Hypomagnesemia following chemotherapy of disseminated testicular tumors].
Hida S; Nishimura K; Nishio Y; Okada Y; Okada K; Yoshida O
Hinyokika Kiyo; 1988 Jan; 34(1):52-60. PubMed ID: 2454015
[TBL] [Abstract][Full Text] [Related]
18. Treatment of poor prognosis nonseminomatous testicular cancer with a "high-dose" platinum combination chemotherapy regimen.
Ozols RF; Deisseroth AB; Javadpour N; Barlock A; Messerschmidt GL; Young RC
Cancer; 1983 May; 51(10):1803-7. PubMed ID: 6187426
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant vinblastine, actinomycin D, bleomycin, cyclophosphamide and cis-platinum chemotherapy regimen with and without maintenance in patients with resected stage IIB testis cancer.
Vugrin D; Whitmore WF; Herr H; Sogani P; Golbey RB
J Urol; 1982 Oct; 128(4):715-7. PubMed ID: 6183456
[TBL] [Abstract][Full Text] [Related]
20. Urinary excretion of N-acetyl-beta-D-glucosaminidase and alanine aminopeptidase in patients receiving amikacin or cis-platinum.
Diener U; Knoll E; Langer B; Rautenstrauch H; Ratge D; Wisser H
Clin Chim Acta; 1981 May; 112(2):149-57. PubMed ID: 6113066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
